Ribociclib (LEE011) | 9481

Ribociclib is a potent cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. LEE011 has been shown to reduce proliferation in 12 of 17 human neuroblastoma-derived cell lines by inducing cytostasis (mean IC₅₀ = 306 nM in sensitive lines).

Ribociclib is a potent cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. LEE011 has been shown to reduce proliferation in 12 of 17 human neuroblastoma-derived cell lines by inducing cytostasis (mean IC₅₀ = 306 nM in sensitive lines).

9481 | Ribociclib (LEE011) DataSheet

Alternate Name/Synonyms: 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide

Appearance: Yellow solid

Formulation: N/A

CAS Number: 1211441-98-3

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: N/A

Molecular Formula: C₂₃H₃₀N₈O

Molecular Weight: 434.54

Cell-Permeable?: Yes

Purity: ≥98% by HPLC

Solubilities: DMSO (~10 mg/ml)

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A potent cyclin-dependent kinase (CDK) inhibitor

MDL Number: N/A

PubChem CID: 44631912

SMILES: CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5

InChi: InChI=1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28)

InChi Key: RHXHGRAEPCAFML-UHFFFAOYSA-N